Global Oligonucleotide synthesis Market

Oligonucleotide Synthesis Market Size, Share, Growth Analysis, By Product(Oligonucleotide-based Drugs (Antisense Oligonucleotide-based drug, siRNA oligonucleotide-based drug, Other oligonucleotide-based drug), Synthesized Oligonucleotides (Primers), By Application(Therapeutic Applications (Disease Type (Neurological Disorders, Rare Diseases, Other Diseases)), Research Applications (PCR), By End User(Hospitals, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, CROs and CMOs), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2107 | Region: Global | Published Date: September, 2024
Pages: 219 | Tables: 67 | Figures: 75

Oligonucleotide Synthesis Market Competitive Landscape

Investing in the development of oligonucleotide synthesis for different disease indications should remain the prime focus of all companies. Reducing the costs of synthesis will be a major area of interest for all oligonucleotide synthesis providers to improve their profitability. Utilizing supportive government initiatives and funding to maximize R&D scope will also be a popular strategy for oligonucleotide synthesis market players in the future. 

Oligonucleotide Synthesis Market Top Player’s Company Profiles

  • Danaher Corporation 
  • Thermo Fisher Scientific Inc. 
  • Merck KGaA 
  • Eurofins Scientific 
  • Agilent Technologies, Inc. 
  • Kaneka Corporation 
  • Azenta, Inc. 
  • Sarepta Therapeutics, Inc. 
  • AstraZeneca 
  • Astellas Pharma Inc. 
  • Jazz Pharmaceuticals PLC 
  • Nippon Shinyaku, Co. Ltd. (NS Pharma, Inc.) 
  • Ionis Pharmaceuticals, Inc. 
  • Novartis AG 
  • OligoMaker ApS (Part of TAG Copenhagen A/S) 
  • Biolegio BV 
  • Biolytic Lab Performance, Inc. 
  • Bio-Synthesis, Inc. 
  • Creative Biogene 
  • Reprocell, Inc.

Oligonucleotide Synthesis Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Oligonucleotide Synthesis Market size was valued at around USD 6 billion in 2022 and is expected to rise from USD 7.3 billion in 2023 to reach a value of USD 26.3 billion by 2031, at a CAGR of 17.4% over the forecast period (2024–2031).

Investing in the development of oligonucleotide synthesis for different disease indications should remain the prime focus of all companies. Reducing the costs of synthesis will be a major area of interest for all oligonucleotide synthesis providers to improve their profitability. Utilizing supportive government initiatives and funding to maximize R&D scope will also be a popular strategy for oligonucleotide synthesis market players in the future.  'Danaher Corporation ', 'Thermo Fisher Scientific Inc. ', 'Merck KGaA ', 'Eurofins Scientific ', 'Agilent Technologies, Inc. ', 'Kaneka Corporation ', 'Azenta, Inc. ', 'Sarepta Therapeutics, Inc. ', 'AstraZeneca ', 'Astellas Pharma Inc. ', 'Jazz Pharmaceuticals PLC ', 'Nippon Shinyaku, Co. Ltd. (NS Pharma, Inc.) ', 'Ionis Pharmaceuticals, Inc. ', 'Novartis AG ', 'OligoMaker ApS (Part of TAG Copenhagen A/S) ', 'Biolegio BV ', 'Biolytic Lab Performance, Inc. ', 'Bio-Synthesis, Inc. ', 'Creative Biogene ', 'Reprocell, Inc.'

Oligonucleotides play a key role in diagnostic tools such as PCR, qPCR, and next-generation sequencing (NGS) and demand for early diagnostics is increasing rapidly. This factor is projected to create new opportunities for oligonucleotide synthesis market growth going forward. 

Use of AI and Automation: Automation and artificial intelligence are being integrated into oligonucleotide synthesis processes, to enhance the accuracy and scalability of the process. Automated synthesizers and AI-driven design tools are projected to be highly popular as they can assist in cost reduction as well.  

North America is projected to account for a dominant share of the global oligonucleotide synthesis market. The presence of a strong medical research infrastructure, supportive government funding for research, and rising use of genetic treatments are helping this region maintain its high market share. The United States and Canada are estimated to be the leading markets in this region as incidence of chronic diseases rises in these countries. The presence of leading pharmaceutical and biotechnology companies will also promote the demand for oligonucleotide synthesis in this region.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Oligonucleotide synthesis Market

Report ID: SQMIG35H2107

$5,300
BUY NOW GET FREE SAMPLE